These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

665 related items for PubMed ID: 29526371

  • 1. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland.
    Rinta-Kokko H, Palmu AA, Auranen K, Nuorti JP, Toropainen M, Siira L, Virtanen MJ, Nohynek H, Jokinen J.
    Vaccine; 2018 Apr 05; 36(15):1934-1940. PubMed ID: 29526371
    [Abstract] [Full Text] [Related]

  • 2. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children--a population-based study.
    Jokinen J, Rinta-Kokko H, Siira L, Palmu AA, Virtanen MJ, Nohynek H, Virolainen-Julkunen A, Toropainen M, Nuorti JP.
    PLoS One; 2015 Apr 05; 10(3):e0120290. PubMed ID: 25781031
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of 10-valent pneumococcal conjugate vaccine estimated with three parallel study designs among vaccine-eligible children in Finland.
    Rinta-Kokko H, Auranen K, Toropainen M, Nuorti JP, Nohynek H, Siira L, Palmu AA.
    Vaccine; 2020 Feb 05; 38(6):1559-1564. PubMed ID: 31791813
    [Abstract] [Full Text] [Related]

  • 4. Pneumococcal Conjugate Vaccine and Clinically Suspected Invasive Pneumococcal Disease.
    Palmu AA, Kilpi TM, Rinta-Kokko H, Nohynek H, Toropainen M, Nuorti JP, Jokinen J.
    Pediatrics; 2015 Jul 05; 136(1):e22-7. PubMed ID: 26077477
    [Abstract] [Full Text] [Related]

  • 5. Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program.
    Richter L, Schmid D, Kanitz EE, Zwazl I, Pöllabauer E, Jasinska J, Burgmann H, Kundi M, Wiedermann U.
    PLoS One; 2019 Jul 05; 14(1):e0210081. PubMed ID: 30629620
    [Abstract] [Full Text] [Related]

  • 6. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M, Christopoulou D, Schmitt HJ.
    BMC Infect Dis; 2015 Oct 14; 15():419. PubMed ID: 26468008
    [Abstract] [Full Text] [Related]

  • 7. Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands.
    Peckeu L, van der Ende A, de Melker HE, Sanders EAM, Knol MJ.
    Vaccine; 2021 Jan 08; 39(2):431-437. PubMed ID: 33243632
    [Abstract] [Full Text] [Related]

  • 8. Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil.
    Brandileone MC, Almeida SCG, Minamisava R, Andrade AL.
    Vaccine; 2018 May 03; 36(19):2559-2566. PubMed ID: 29650385
    [Abstract] [Full Text] [Related]

  • 9. Invasive disease potential of Streptococcus pneumoniae serotypes before and after 10-valent pneumococcal conjugate vaccine introduction in a rural area, southern Mozambique.
    Massora S, Lessa FC, Moiane B, Pimenta FC, Mucavele H, Chaúque A, Cossa A, Verani JR, Tembe N, da Gloria Carvalho M, Muñoz-Almagro C, Sigaúque B.
    Vaccine; 2019 Dec 03; 37(51):7470-7477. PubMed ID: 31575493
    [Abstract] [Full Text] [Related]

  • 10. Long-term surveillance of invasive pneumococcal disease: The impact of 10-valent pneumococcal conjugate vaccine in the metropolitan region of Salvador, Brazil.
    Reis JN, Azevedo J, de Oliveira AML, Menezes APO, Pedrosa M, Dos Santos MS, Ribeiro LC, Freitas HF, Gouveia EL, Teles MB, Carvalho MDG, Reis MG, Nascimento-Carvalho C, Verani JR.
    Vaccine; 2024 Jan 25; 42(3):591-597. PubMed ID: 38184393
    [Abstract] [Full Text] [Related]

  • 11. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V, McIntyre P.
    Clin Infect Dis; 2017 Jan 15; 64(2):175-183. PubMed ID: 27986682
    [Abstract] [Full Text] [Related]

  • 12. Recurrent invasive pneumococcal disease in children--host factors and vaccination response.
    Ingels HA.
    Dan Med J; 2015 Jul 15; 62(7):. PubMed ID: 26183055
    [Abstract] [Full Text] [Related]

  • 13. Long-term population impact of infant 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in adults in Finland.
    Nuorti JP, Rinta-Kokko H, Toropainen M, Siira L, Nohynek H, Palmu AA.
    Vaccine; 2022 Sep 29; 40(41):5950-5958. PubMed ID: 36075797
    [Abstract] [Full Text] [Related]

  • 14. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P, Lefebvre B, Deceuninck G, Longtin J.
    Vaccine; 2018 Jan 08; 36(3):421-426. PubMed ID: 29224962
    [Abstract] [Full Text] [Related]

  • 15. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.
    Vaccine; 2013 Dec 16; 31(52):6232-8. PubMed ID: 24176490
    [Abstract] [Full Text] [Related]

  • 16. Pediatric invasive pneumococcal disease in Taiwan following a national catch-up program with the 13-valent pneumococcal conjugate vaccine.
    Wei SH, Chiang CS, Chiu CH, Chou P, Lin TY.
    Pediatr Infect Dis J; 2015 Mar 16; 34(3):e71-7. PubMed ID: 25247584
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
    Savulescu C, Krizova P, Valentiner-Branth P, Ladhani S, Rinta-Kokko H, Levy C, Mereckiene J, Knol M, Winje BA, Ciruela P, de Miguel S, Guevara M, MacDonald L, Kozakova J, Slotved HC, Fry NK, Pekka Nuorti J, Danis K, Corcoran M, van der Ende A, Vestrheim DF, Munoz-Almagro C, Sanz JC, Castilla J, Smith A, Colzani E, Pastore Celentano L, Hanquet G, SpIDnet VE study group.
    Vaccine; 2022 Jun 23; 40(29):3963-3974. PubMed ID: 35637067
    [Abstract] [Full Text] [Related]

  • 18. Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015.
    Wagenvoort GH, Sanders EA, Vlaminckx BJ, de Melker HE, van der Ende A, Knol MJ.
    Euro Surveill; 2017 Mar 09; 22(10):. PubMed ID: 28300529
    [Abstract] [Full Text] [Related]

  • 19. Serotype distribution of Streptococcus pneumoniae isolated from patients with invasive pneumococcal disease in Brazil before and after ten-pneumococcal conjugate vaccine implementation.
    dos Santos SR, Passadore LF, Takagi EH, Fujii CM, Yoshioka CR, Gilio AE, Martinez MB.
    Vaccine; 2013 Dec 09; 31(51):6150-4. PubMed ID: 23747454
    [Abstract] [Full Text] [Related]

  • 20. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study.
    Hammitt LL, Etyang AO, Morpeth SC, Ojal J, Mutuku A, Mturi N, Moisi JC, Adetifa IM, Karani A, Akech DO, Otiende M, Bwanaali T, Wafula J, Mataza C, Mumbo E, Tabu C, Knoll MD, Bauni E, Marsh K, Williams TN, Kamau T, Sharif SK, Levine OS, Scott JAG.
    Lancet; 2019 May 25; 393(10186):2146-2154. PubMed ID: 31000194
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.